Kimberly Manhard

Kimberly Manhard is recorded as Board Member at Inhibrx Biosciences, Inc. (INBX) since January 1, 2024. The newest filing on record that lists Kimberly Manhard as Board Member at Inhibrx Biosciences, Inc. (INBX) is dated April 23, 2026. Kimberly Manhard was last confirmed as Board Member at Heron Therapeutics, Inc. (HRTX) in a filing dated May 1, 2023. Earlier roles on record: Board Member at Heron Therapeutics, Inc. (HRTX) until February 21, 2023. Heron Therapeutics, Inc. reported in an 8-K filed June 12, 2023 that Kimberly Manhard resigned as Executive Vice President, Drug Development, effective June 6, 2023. Heron Therapeutics, Inc. reported in an 8-K filed February 22, 2023 that Kimberly Manhard resigned as director, effective February 21, 2023. The proxy statement of Heron Therapeutics, Inc. reports total compensation of $1,447,107 for Kimberly Manhard in fiscal 2022, including a base salary of $545,834. Disclosed compensation is on record for 5 fiscal years. Acadia Pharmaceuticals Inc is classified in the Biotechnology industry within the Healthcare sector. Inhibrx Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Acadia Pharmaceuticals Inc includes Catherine Owen Adams (CEO and Board Member), Stephen R. Biggar (Chairman and Board Member), Mark C. Schneyer (CFO) and 7 others.